Short Interest in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Drops By 60.9%

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 29,300 shares, a drop of 60.9% from the January 31st total of 74,900 shares. Based on an average daily volume of 332,300 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Investors Weigh In On Chemomab Therapeutics

A number of large investors have recently added to or reduced their stakes in CMMB. XTX Topco Ltd boosted its holdings in shares of Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Chemomab Therapeutics in the 4th quarter valued at $26,000. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Chemomab Therapeutics in the 3rd quarter valued at $1,907,000. Institutional investors and hedge funds own 46.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Maxim Group increased their target price on Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Oppenheimer reissued an “outperform” rating and set a $11.00 price target (down previously from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Price Performance

Shares of NASDAQ:CMMB opened at $1.68 on Friday. The company has a market capitalization of $24.12 million, a P/E ratio of -1.68 and a beta of 0.66. Chemomab Therapeutics has a 1 year low of $0.58 and a 1 year high of $2.55. The business’s 50 day simple moving average is $1.97 and its 200 day simple moving average is $1.74.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).